Acadia Pharmaceuticals | ACAD - 销售和管理费用

金融业

USD 19.71

USD 1.74B

现金及等价物

USD 956.47M

USD 28.32M

USD 1.22B

USD 361.44M

USD 50.79M

USD 37.84M

USD -1.62M

653

EPS每股收益

USD 0.18

股本和储备

USD 1.31B

USD 279.64M

债务利息支出

USD 0

USD 8.06M

USD 0

USD 3.2B

USD 31.5M

USD 270.12M

USD 37.84M

普通股股本

USD 171.09M

11.33

USD 46.47M

USD 307.96M

销售和管理费用

USD 148.57M

USD 108.67M

贸易债权人

USD 44.57M

应收帐款人

USD 166.33M

	销售和管理费用	更改		日
Acadia Pharmaceuticals	USD 148.57M		12.22M	2026-06
ALKERMES	USD 196.64M		67.96M	2026-06
Alnylam Pharmaceuticals	USD 347.92M		65.41M	2026-06
Biogen	USD 709.7M		155.4M	2026-06
BioMarin Pharmaceutical	USD 395.55M		137.27M	2026-06
Bristol-Myers Squibb	USD 1.83B		209M	2026-06
Cara Therapeutics	USD 2.09M		96K	2026-03
Corcept Therapeutics	USD 156.9M		28.85M	2026-06
Cytokinetics	USD 104.4M		499K	2026-06
Eisai	JPY 114.83B		4.71B	2026-06
Eli Lilly	USD 3.43B		496M	2026-06
Incyte	USD 351.73M		23.64M	2026-06
J&J	USD 6.25B		168M	2026-09
Moderna	USD 216M		43M	2026-06
Neurocrine Biosciences	USD 383.1M		64.6M	2026-06
Pfizer	USD 3.41B		496M	2026-06
Prothena	USD 12.67M		5.02M	2026-03
PTC Therapeutics	USD 73.89M		13.31M	2026-03
Sarepta Therapeutics	USD 107.6M		53.57M	2026-06
Ultragenyx Pharmaceutical	USD 88M		1000K	2026-03
Vanda Pharmaceuticals	USD 39.28M		1.71M	2024-12
Vertex Pharmaceuticals	USD 582.2M		88.5M	2026-06